| Robust (n = 71) | Prefrail (n = 71) | Frail (n = 57) | P-value* | ||||||
Current age (years), n (%) |
|
|
|
| ||||||
[50 - 59] | 53 (74.65) | 40 (56.34) | 25 (43.86) | 0.001* | ||||||
[60 - 69] | 17 (23.94) | 23 (32.39) | 19 (33.33) | |||||||
≥70 | 1 (1.41) | 8 (11.27) | 13 (22.81) | |||||||
Age at ART inclusion (years) |
|
|
|
| ||||||
<50 | 64 (90.14) | 50 (70.42) | 39 (68.42) | 0.002* | ||||||
≥50 | 7 (9.86) | 21 (29.58) | 18 (31.58) | |||||||
Sex, n (%) |
|
|
|
| ||||||
Women | 40 (56.34) | 51 (71.83) | 35 (61.4) | 0.15 | ||||||
Men | 31 (43.66) | 20 (28.17) | 22 (38.6) | |||||||
HIV profile, n (%) |
|
|
|
| ||||||
1 | 70 (98.6) | 61 (85.9) | 47 (82.46) | 0.007* | ||||||
2 | 1 (1.41) | 9 (12.7) | 8 (14.04) | |||||||
1 + 2 | - | 1 (1.41) | 2 (3.51) | |||||||
Line of traitement, n (%) |
|
|
|
| ||||||
First | 68 (95.77) | 68 (95.77) | 54 (94.74) | 0.93 | ||||||
Second | 3 (4.23) | 3 (4.23) | 2 (3.51) | |||||||
Third | - | - | 1 (1.75) | |||||||
WHO stage OMS at inclusion |
|
|
|
| ||||||
I | 20(28.17) | 22 (30.99) | 10 (17.54) | 0.27 | ||||||
II | 22 (30.99) | 17 (23.94) | 14 (24.56) | |||||||
III | 24 (33.8) | 27 (38.03) | 23 (40.35) | |||||||
IV | 5 (7.04) | 5 (7.04) | 10 (17.54) | |||||||
Nadir TCD4+ Lymphocyte counts (elements/mm3) |
|
|
|
| ||||||
<200 | 41 (57.75) | 41 (57.75) | 29 (50.88) | 0.67 | ||||||
≥200 | 30 (42.25) | 30 (42.25) | 28 (4912) | |||||||
Duration under ART (months) |
|
|
|
| ||||||
<120 | 11 (15.49) | 13 (18.31) | 11 (19.3) | 0.34 | ||||||
120 - 240 | 55 (77.46) | 51 (71.83) | 36 (63.16) | |||||||
>240 | 5 (7.04) | 7 (9.86) | 10 (17.54) | |||||||
Current therapeutic regimen |
|
|
|
| ||||||
Sans TDF | 3 (4.23) | 2 (2.82) | 1 (1.75) | 0.04* | ||||||
Avec TDF | 68 (95.77) | 69 (97.18) | 56 (98.25) | |||||||
Duration of TDF exposure |
|
|
|
| ||||||
<10ans | 52 (73.24) | 55 (77.46) | 7 (12.28) | 0.001* | ||||||
>10ans | 19 (26.76) | 16 (22.54) | 50 (87.72) |
| ||||||
Current WHO stage |
|
|
|
| ||||||
I | 70 (98.59) | 70 (98.59) | 54 (94.74) | 0.79 | ||||||
II | 1 (1.41) | 1 (1.41) | 1 (1.75) | |||||||
III | - | - | 1 (1.75) | |||||||
IV | - | - | 1 (1.75) | |||||||
Current viral load (copies/ml) |
|
|
|
| ||||||
<40 | 71 (100) | 70 (98.59) | 55 (96.59) |
| ||||||
>40 | - | 1 (1.41) | 2 (3.51) | |||||||
Body mass index |
|
|
|
| ||||||
Underweight | 5 (7.04) | 6 (8.45) | 8 (14.04) | 0.29 | ||||||
Normal | 33 (46.48) | 27 (38.03) | 31 (54.39) | |||||||
Overweight/obesity | 33 (46.48) | 38 (53.53) | 18 (31.58) | |||||||
Sensory disorders |
|
|
|
| ||||||
No | 71 (100) | 64 (90.14) | 47 (82.46) | 0.001* | ||||||
Yes | - | 7 (9.86) | 10 (17.54) | |||||||
Comorbidities |
|
|
|
| ||||||
<1 | 45 (63.38) | 38 (53.52) | 35 (61.4) | 0.65 | ||||||
1 - 2 | 18 (25.35) | 19 (26.76) | 14 (24.55) | |||||||
≥3 | 8 (11.27) | 14 (19.72) | 8 (14.04) | |||||||
Charlson comorbidity Index |
|
|
|
| ||||||
<1 | 52 (73.24) | 44 (61.97) | 37 (64.91) | 0.69 | ||||||
1 - 2 | 11 (15.49) | 15 (21.13) | 11 (19.3) | |||||||
≥3 | 8 (11.27) | 12 (16.9) | 9 (15.79) | |||||||
Polypharmacy |
|
|
|
| ||||||
≤4 | 58 (81.69) | 45 (63.38) | 34 (59.65) | 0.013* | ||||||
≥5 | 13 (18.31) | 26 (36.62) | 23 (40.35) | |||||||
MNA |
|
|
|
| ||||||
Normal | 63 (88.73) | 55 (77.46) | 16 (28.07) | 0.001* | ||||||
Risk of malnutrition | 8 (11.27) | 16 (22.54) | 35 (61.40) | |||||||
Malnourished | - | - | 6 (10.53) | |||||||